Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Allergan's Ubrogepant Succeeds In Second Acute Migraine Phase III Study

Apr 28 2018

• By Mandy Jackson

Human brain illustrated with millions of small nerves - Conceptual 3d render

Related Content

As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past

Apr 25 2018

Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m

Jan 19 2017

Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins

May 12 2017

Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang

Feb 06 2018

Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis

Mar 15 2018

Biohaven Posts Positive Migraine Results, But Investors Are Wary

Mar 27 2018

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Sep 30 2016

Allergan migraine portfolio grows with Merck CGRP antagonists

Jul 08 2015

Related Companies

Allergan plc

Amgen, Inc.

Novartis AG

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Alder Biopharmaceuticals, Inc.

Merck & Co., Inc.

Biohaven Pharmaceutical Holding Company Ltd.

Bristol Myers Squibb Company

CoLucid Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Drug Safety Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window